trending Market Intelligence /marketintelligence/en/news-insights/trending/xibjfwtlgomelwgys81umg2 content esgSubNav
In This List

I-O company Surface Oncology files for IPO, to raise $11.5M in placement

Blog

Funding Social and Affordable Housing: A Credit Perspective

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals


I-O company Surface Oncology files for IPO, to raise $11.5M in placement

Cambridge, Mass.-based Surface Oncology Inc. filed for an IPO of its common stock, hoping to raise up to $75 million.

The immuno-oncology company plans to list its shares on the Nasdaq Global Market under the symbol SURF.

Goldman Sachs & Co. LLC and Cowen and Co. LLC are acting as the representatives of the underwriters for the offering.

Meanwhile, Novartis Institutes for BioMedical Research Inc. — a unit of Novartis AG — also agreed to buy $11.5 million worth of Surface Oncology shares in a concurrent private placement.

Surface plans to use the net proceeds from the IPO and the placement for operating expenses and capital expenditure requirements.

Surface Oncology develops cancer therapies by adjusting a patient's immune system to fight cancer.